4.7 based on 14 reviewsView this provider's reviews
Patient satisfaction ratings and reviews are based on personal opinions. Before you choose any doctor you should take into account their background, training, specialized experience AND their patient satisfaction to ensure they are the right fit for you.
Dr. Jeffrey Holzbeierlein, MD is an urology specialist in Kansas City, KS and has been practicing for 16 years. He graduated from University Of Oklahoma / Health Sciences Center in 1994 and specializes in urology.Read his story
We're trying something new with Top Care Areas.Was it helpful for you?YesNo
Dr. Holzbeierlein's bio
This content was provided by Dr. Holzbeierlein "Dr. Jeffrey Holzbeierlein is the John W. Weigel Endowed Professor of Urology, the Director of Urologic Oncology, and the Interim Chair of the Department of Urology at the University of Kansas Medical Center. He was raised in Edmond, Oklahoma and received his undergraduate degree from Vanderbilt University and his medical degree from the University of Oklahoma. He joined the faculty at KU after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center, in New York. Dr. Holzbeierlein is the current President of the South Central Section of the American Urological Association. He is the Secretary of the Society of Urologic Oncology (SUO), where he is the past Chair of the Fellowship Committee and serves on the Executive Board of the SUO. For this work, he received the SUO Distinguished Service Award, in 2013. He has served on the American Board of Urology Examination Committee and is a past Assistant Editor for the Journal of Urology. He currently is a member of the Oral Boards Committee for the American Board of Urology and has served on numerous AUA Committees, including the Practice Guidelines Committee and the Public Media Committee, and he has completed the AUA Leadership Program. He is the Chair-elect for the Program Committee for GU ASCO. In addition, he is a Fellow of the American College of Surgeons and serves on the Kansas section of the ACS selection committee. Dr. Holzbeierlein is also the past Chair and founding member of the Young Urologic Oncologists Section of the Society of Urologic Oncology. He is a reviewer for the Journal of Urology, Cancer, and Urologic Oncology. He has also been awarded the Resident Mentoring Award for faculty at The University of Kansas Hospital. Dr. Holzbeierlein serves on numerous hospital committees at the University of Kansas Health System and is the past co-director of the K-Inbre Translational Research Core, and the Director of the Genitourinary Disease Working Group. He is also the Director of the Burns and McDonnell High Risk Prostate Cancer Prevention and Survivorship Clinic at the University of Kansas Cancer Center. Dr. Holzbeierlein has published numerous peer-reviewed journal articles, and has numerous presentation and abstracts in journals and textbooks dealing with urologic oncology. He has been an annual lecturer for an AUA Course focusing on the Management of High Risk Superficial Bladder Cancer that was selected as one of the "best courses" at the AUA. He has intramural and extramural grant support including a co-investigator on an R01, and as PI on several investigator initiated trials. Dr. Holzbeierlein specializes in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. His research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy. He lives in Kansas City with his wife Jill, and their 4 children, and is civically active at the Hope Lodge of Kansas City and Maison de Naissance."
This content was provided by Dr. Holzbeierlein "I specialize in the treatment of genitourinary malignancies including prostate, bladder, kidney, testicular, and penile cancers. My research interest includes the androgen receptor as a target of Hsp90 inhibitors in prostate cancer and clinically decreasing the morbidity associated with cystectomy."